Evidence map›Paper›PMID 27722429›Full record

ReviewMetallomics : integrated biometal science2016

Tuning the metabolism of the anticancer drug cisplatin with chemoprotective agents to improve its safety and efficacy.

Melani Sooriyaarachchi, Graham N George, Ingrid J Pickering, Aru Narendran, Jürgen Gailer

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Metallomics : integrated biometal science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Use of Sodium Thiosulfate as an Otoprotectant in Patients With Cancer Treated With Platinum Compounds: A Review of the Literature.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. The Role of Tumour Metabolism in Cisplatin Resistance.Frontiers in molecular biosciences · 2021
    Review
  9. Review
  10. Review
  11. Article
  12. SEC hyphenated to a multielement-specific detector unravels the degradation pathway of a bimetallic anticancer complex in human plasma.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2020
    Article
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Melani SooriyaarachchiDepartment of Chemistry, University of Calgary, 2500 University Drive NW, Calgary, AB T2N 1N4, Canada. jgailer@ucalgary.ca.
Graham N GeorgeMolecular and Environmental Science Research Group, Department of Geological Sciences, University of Saskatchewan, Saskatoon, S7N 5E2, Canada and Toxicology Centre, University of Saskatchewan, Saskatoon, SK S7N 5B3, Canada and Department of Chemistry, University of Saskatchewan, Saskatoon, SK S7N 5C9, Canada.
Ingrid J PickeringMolecular and Environmental Science Research Group, Department of Geological Sciences, University of Saskatchewan, Saskatoon, S7N 5E2, Canada and Toxicology Centre, University of Saskatchewan, Saskatoon, SK S7N 5B3, Canada and Department of Chemistry, University of Saskatchewan, Saskatoon, SK S7N 5C9, Canada.
Aru NarendranDivision of Pediatric Oncology, Alberta Children's Hospital, Calgary, AB T3B 6A8, Canada.
Jürgen GailerDepartment of Chemistry, University of Calgary, 2500 University Drive NW, Calgary, AB T2N 1N4, Canada. jgailer@ucalgary.ca.
University of Calgary · CAUniversity of Saskatchewan · CAAlberta Children's Hospital · CA

Funding

X-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6M
CIHRNIGMS NIH HHS P41 GM103393
6 · The paper itself

Abstract

Numerous in vivo studies have shown that the severe toxic side-effects of intravenously administered cisplatin can be significantly reduced by the co-administration of sulfur-containing 'chemoprotective agents'. Using a metallomics approach, a likely biochemical basis for these potentially useful observations was only recently uncovered and appears to involve the reaction of chemoprotective agents with cisplatin-derived Pt-species in human plasma to form novel platinum-sulfur complexes (PSC's). We here reveal aspects of the structure of two PSC's and establish the identification of an optimal chemoprotective agent to ameliorate the toxic side-effects of cisplatin, while leaving its antineoplastic activity largely intact, as a feasible research strategy to transform cisplatin into a safer and more effective anticancer drug.

Indexed as

Drug DesignAntineoplastic AgentsCisplatinHumansNeoplasmsPlatinum CompoundsProtective AgentsSulfur CompoundsAntineoplastic AgentsCisplatinPlatinum CompoundsProtective AgentsSulfur Compounds

Identifiers

PMID27722429
PMCPMC5123636
OpenAlexW2524578811

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.